Cerebrolysin
Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from purified pig brain proteins. It is approved in many countries for stroke, traumatic brain injury, and dementia.
Mechanism of Action
Contains multiple neurotrophic factors that promote neuroplasticity, reduce neuronal apoptosis, and support synaptic function. Has both neurotrophic and neuroprotective properties.
Typical Dosage (Research)
Clinical dosing: 10-30ml IV daily for acute conditions. Research use: 5-10ml IM daily for cognitive enhancement. Treatment courses typically last 10-20 days.
Administered via intramuscular or intravenous injection. IV administration is typically used in clinical settings. IM can be used for research purposes.
Side Effects & Risks
Generally well-tolerated. May cause dizziness, headache, sweating, or injection site reactions. Rare cases of agitation or confusion.
Not FDA-approved in the US. Should be avoided in severe renal impairment and epilepsy. Quality and sourcing concerns outside clinical settings.
Who Uses Cerebrolysin
Stroke recovery patients, those with traumatic brain injury, individuals with cognitive decline, biohackers seeking neuroprotection.